Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15652
UPID:
JHD2C_HUMAN
Alternative names:
Jumonji domain-containing protein 1C; Thyroid receptor-interacting protein 8
Alternative UPACC:
Q15652; A0T124; Q5SQZ8; Q5SQZ9; Q5SR00; Q7Z3E7; Q8N3U0; Q96KB9; Q9P2G7
Background:
The Probable JmjC domain-containing histone demethylation protein 2C, also known as Jumonji domain-containing protein 1C and Thyroid receptor-interacting protein 8, plays a pivotal role in the histone code by specifically demethylating 'Lys-9' of histone H3. This action not only alters chromatin structure but also influences gene expression, with implications for hormone-dependent transcriptional activation.
Therapeutic significance:
Understanding the role of Probable JmjC domain-containing histone demethylation protein 2C could open doors to potential therapeutic strategies.